# ZYBT (Zhengye Biotechnology Holding Limited) - SEC EDGAR Financial Statements

> Zhengye Biotechnology Holding Limited reported ¥116.4M in revenue and a net loss of ¥69.78M for the fiscal year ended December 31, 2025 (down 37.6% year over year), with a 20.5% gross margin and a -60.6% operating margin.

- Canonical: https://convexityos.com/fundamentals/ZYBT
- Markdown: https://convexityos.com/fundamentals/ZYBT.md
- SEC CIK: 0001975641
- Reporting currency: CNY
- Latest filing period: December 31, 2025
- Last synced: Nov 20, 2026, 05:51 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001975641&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | ¥116.4M | -37.6% YoY |
| Operating Income | FY 2025 | -¥70.51M | -60.6% margin |
| Net Income | FY 2025 | -¥69.78M | -60.0% net margin |
| Diluted EPS | FY 2025 | -- | Split-adjusted |
| Free Cash Flow | FY 2025 | ¥12.32M | 10.6% FCF margin |
| Cash & ST Investments | Dec 31, 2025 | ¥51.89M | Total debt: ¥75.08M |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Revenue** | ¥116.4M | ¥186.4M | ¥211.7M | ¥260.3M |
| Cost of Revenue | ¥92.49M | ¥95.06M | ¥94.14M | ¥112.4M |
| **Gross Profit** | ¥23.87M | ¥91.30M | ¥117.5M | ¥147.9M |
| Research & Development | ¥18.01M | ¥12.79M | ¥11.90M | ¥13.42M |
| Selling, General & Admin | ¥74.92M | ¥63.84M | ¥64.33M | ¥58.89M |
| Total Operating Expenses | ¥94.38M | ¥74.86M | ¥72.52M | ¥82.05M |
| **Operating Income** | -¥70.51M | ¥16.44M | ¥44.99M | ¥65.83M |
| **EBITDA** | -¥44.62M | ¥40.60M | ¥68.90M | ¥84.63M |
| Interest Income | ¥96K | ¥231K | ¥312K | ¥114K |
| Interest Expense | ¥3.40M | ¥4.04M | ¥4.42M | ¥2.84M |
| Income Before Tax | -¥71.87M | ¥14.39M | ¥43.76M | ¥63.91M |
| Income Tax Expense | ¥11.10M | ¥924K | ¥6.25M | ¥8.17M |
| **Net Income** | -¥69.78M | ¥11.31M | ¥31.46M | ¥46.73M |
| Basic EPS | -- | ¥0.25 | ¥0.69 | ¥1.02 |
| **Diluted EPS** | -- | ¥0.25 | ¥0.69 | ¥1.02 |
| Basic Shares Outstanding | 47.3M | 45.7M | 45.7M | 45.7M |
| Diluted Shares Outstanding | 47.3M | 45.7M | 45.7M | 45.7M |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | ¥50.33M | ¥18.60M | ¥15.07M |
| Short-Term Investments | ¥1.56M | ¥1.43M | ¥1.22M |
| **Cash & Short-Term Investments** | ¥51.89M | ¥20.04M | ¥16.30M |
| Accounts Receivable, Net | ¥18.48M | ¥59.56M | ¥74.17M |
| Inventory | ¥39.17M | ¥58.22M | ¥58.30M |
| **Total Current Assets** | ¥137.4M | ¥177.6M | ¥189.2M |
| Property, Plant & Equipment, Net | ¥236.8M | ¥255.2M | ¥263.2M |
| Intangible Assets | ¥47.08M | ¥14.85M | ¥16.30M |
| **Total Non-Current Assets** | ¥299.1M | ¥315.7M | ¥310.6M |
| **Total Assets** | ¥436.5M | ¥493.2M | ¥499.9M |
| Accounts Payable | ¥44.01M | ¥42.96M | ¥45.66M |
| Short-Term Debt | ¥65.80M | ¥81.63M | ¥79.86M |
| Deferred Revenue (Current) | ¥4.75M | ¥3.48M | ¥3.88M |
| **Total Current Liabilities** | ¥120.5M | ¥135.9M | ¥150.2M |
| Long-Term Debt | ¥8.85M | ¥4.80M | ¥9.99M |
| **Total Non-Current Liabilities** | ¥9.28M | ¥4.80M | ¥10.38M |
| **Total Liabilities** | ¥129.8M | ¥140.7M | ¥160.6M |
| **Total Debt (incl. Leases)** | ¥75.08M | ¥86.43M | ¥89.85M |
| Common Stock | -- | ¥8.0K | ¥8.0K |
| Retained Earnings | -¥21.63M | ¥48.15M | ¥38.38M |
| Accumulated Other Comp. Income | -¥1.93M | ¥3.0K | -- |
| **Total Stockholders' Equity** | ¥249.8M | ¥284.0M | ¥272.9M |
| Total Equity | ¥306.7M | ¥352.5M | ¥339.3M |

### Balance Sheet (Quarterly)

| Line Item | Dec 2025 | Dec 2024 | Dec 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | ¥50.33M | ¥18.60M | ¥15.07M |
| Short-Term Investments | ¥1.56M | ¥1.43M | ¥1.22M |
| **Cash & Short-Term Investments** | ¥51.89M | ¥20.04M | ¥16.30M |
| Accounts Receivable, Net | ¥18.48M | ¥59.56M | ¥74.17M |
| Inventory | ¥39.17M | ¥58.22M | ¥58.30M |
| **Total Current Assets** | ¥137.4M | ¥177.6M | ¥189.2M |
| Property, Plant & Equipment, Net | ¥236.8M | ¥255.2M | ¥263.2M |
| Intangible Assets | ¥47.08M | ¥14.85M | ¥16.30M |
| **Total Non-Current Assets** | ¥299.1M | ¥315.7M | ¥310.6M |
| **Total Assets** | ¥436.5M | ¥493.2M | ¥499.9M |
| Accounts Payable | ¥44.01M | ¥42.96M | ¥45.66M |
| Short-Term Debt | ¥65.80M | ¥81.63M | ¥79.86M |
| Deferred Revenue (Current) | ¥4.75M | ¥3.48M | ¥3.88M |
| **Total Current Liabilities** | ¥120.5M | ¥135.9M | ¥150.2M |
| Long-Term Debt | ¥8.85M | ¥4.80M | ¥9.99M |
| **Total Non-Current Liabilities** | ¥9.28M | ¥4.80M | ¥10.38M |
| **Total Liabilities** | ¥129.8M | ¥140.7M | ¥160.6M |
| **Total Debt (incl. Leases)** | ¥75.08M | ¥86.43M | ¥89.85M |
| Common Stock | -- | ¥8.0K | ¥8.0K |
| Retained Earnings | -¥21.63M | ¥48.15M | ¥38.38M |
| Accumulated Other Comp. Income | -¥1.93M | ¥3.0K | -- |
| **Total Stockholders' Equity** | ¥249.8M | ¥284.0M | ¥272.9M |
| Total Equity | ¥306.7M | ¥352.5M | ¥339.3M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| Net Income | -¥82.97M | ¥13.47M | ¥37.51M | ¥55.74M |
| Depreciation & Amortization | ¥25.88M | ¥24.16M | ¥23.91M | ¥18.80M |
| Change in Receivables | ¥39.71M | ¥16.34M | ¥31.04M | -¥24.96M |
| Change in Inventory | ¥6.25M | -¥5.88M | -¥12.90M | -¥12.32M |
| Change in Payables | -¥3.36M | -¥404K | -¥35.61M | -¥9.67M |
| **Operating Cash Flow** | ¥13.33M | ¥41.05M | ¥48.18M | ¥17.34M |
| Capital Expenditure | -¥1.01M | -¥13.59M | -¥7.40M | -¥27.33M |
| **Free Cash Flow** | ¥12.32M | ¥27.46M | ¥40.79M | -¥9.99M |
| **Investing Cash Flow** | -¥12.63M | -¥27.66M | -¥11.77M | -¥27.33M |
| Dividends Paid | -- | -¥16.02M | -¥39.45M | -¥21.43M |
| **Financing Cash Flow** | ¥32.31M | -¥22.13M | -¥18.98M | ¥13.46M |
| **Net Change in Cash** | ¥31.73M | -¥8.58M | ¥17.44M | ¥3.46M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
| --- | --- | --- | --- | --- |
| **Gross Margin** | 20.5% | 49.0% | 55.5% | 56.8% |
| **Operating Margin** | -60.6% | 8.8% | 21.3% | 25.3% |
| **Net Profit Margin** | -60.0% | 6.1% | 14.9% | 18.0% |
| Return on Equity (ROE) | -27.9% | 4.0% | 11.5% | -- |
| Return on Assets (ROA) | -16.0% | 2.3% | 6.3% | -- |
| Current Ratio | 1.14x | 1.31x | 1.26x | -- |
| Quick Ratio | 0.82x | 0.88x | 0.87x | -- |
| Debt to Equity | 0.30x | 0.30x | 0.33x | -- |
| **Revenue Growth (YoY)** | -37.6% | -12.0% | -18.7% | -- |
| Gross Profit Growth (YoY) | -73.9% | -22.3% | -20.5% | -- |
| Operating Income Growth (YoY) | -528.9% | -63.5% | -31.7% | -- |
| **Net Income Growth (YoY)** | -717.0% | -64.0% | -32.7% | -- |
| EPS Growth (YoY) | -- | -63.8% | -32.4% | -- |
| Operating Cash Flow Growth (YoY) | -67.5% | -14.8% | +178.0% | -- |
| Free Cash Flow Growth (YoY) | -55.1% | -32.7% | -- | -- |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
